Cargando…

Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China

BACKGROUND: Sunitinib was approved several years ago as a first-line drug for treating metastatic renal cell carcinoma (mRCC); however, its high price and broad side effects when administered at the standard dose have limited its clinical use. A clinical trial (NCT02072031) confirmed that anlotinib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Jingyang, Fang, Qingxia, Zheng, Xiaochun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9904460/ https://www.ncbi.nlm.nih.gov/pubmed/36749752 http://dx.doi.org/10.1371/journal.pone.0281402

Ejemplares similares

Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom
por: Amdahl, Jordan, et al.
Publicado: (2017)

Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
por: Géczi, Lajos, et al.
Publicado: (2020)

Outcomes of axitinib versus sunitinib as first‐line therapy to patients with metastatic renal cell carcinoma in the immune‐oncology era
por: Numakura, Kazuyuki, et al.
Publicado: (2021)

A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma
por: Lu, Peiyao, et al.
Publicado: (2020)

Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States
por: Li, SiNi, et al.
Publicado: (2021)

Metastatic Tumor Burden and Loci as Predictors of First Line Sunitinib Treatment Efficacy in Patients with Renal Cell Carcinoma
por: Czarnecka, Anna M., et al.
Publicado: (2019)

Efficacy and Prognostic Factors of Sunitinib as First-Line Therapy for Patients With Metastatic Renal Cell Carcinoma in an Arab Population
por: Badran, Ahmed, et al.
Publicado: (2020)

Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis
por: Sheng, Xinan, et al.
Publicado: (2016)

Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib
por: Mickisch, G, et al.
Publicado: (2010)

Comparative Efficacy, Safety, and Costs of Sorafenib vs. Sunitinib as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
por: Deng, Huan, et al.
Publicado: (2019)

Case report: Significant benefits of tislelizumab combined with anlotinib in first-line treatment of metastatic renal pelvic urothelial carcinoma with sarcomatoid carcinoma differentiation
por: Zhu, Shibin, et al.
Publicado: (2022)

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
por: Knox, J J, et al.
Publicado: (2018)

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
por: Knox, J. J., et al.
Publicado: (2017)

Regarding: ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’
por: Porta, C
Publicado: (2010)

Comment on ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’
por: Charbonneau, C, et al.
Publicado: (2010)

Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib
por: Mickisch, G H J, et al.
Publicado: (2010)

Systematic review and cost-effectiveness of pharmacokinetically guided sunitinib individualized treatment for patients with metastatic renal cell carcinoma
por: Chen, Tingting, et al.
Publicado: (2022)

Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis
por: Wen, Tingyu, et al.
Publicado: (2017)

Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness
por: Thompson Coon, J S, et al.
Publicado: (2009)

Efficacy of First-Line Targeted Therapy in Real-World Korean Patients with Metastatic Renal Cell Carcinoma: Focus on Sunitinib and Pazopanib
por: Kim, Myung Soo, et al.
Publicado: (2018)

Analysis of Efficacy and Toxicity Profile of First-Line Sunitinib or Pazopanib in Metastatic Clear Cell Renal Cell Carcinoma in the Brazilian Population
por: Isaacsson Velho, Pedro, et al.
Publicado: (2018)

Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors
por: Zhang, Hai-Liang, et al.
Publicado: (2017)

Induction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma
por: Iyer, Ridhima, et al.
Publicado: (2017)

Complete remission of metastatic renal cell carcinoma to the bone with sunitinib
por: Yoshimura, Akihiro, et al.
Publicado: (2020)

The role of netrin-1 in metastatic renal cell carcinoma treated with sunitinib
por: Frees, Sebastian, et al.
Publicado: (2018)

Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma
por: Cai, Wen, et al.
Publicado: (2017)

Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First-Line Setting
por: Nikic, Predrag, et al.
Publicado: (2022)

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma
por: Hutson, T E, et al.
Publicado: (2014)

Buccodental side effects of sunitinib in patients with metastatic renal cell carcinoma
por: Gilabert, M, et al.
Publicado: (2013)

Intolerance to Sunitinib Treatment in Hemodialysis Patients With Metastatic Renal Cell Carcinoma
por: Yildiz, Ibrahim, et al.
Publicado: (2014)

Clinical significance of sunitinib‐associated macrocytosis in metastatic renal cell carcinoma
por: Bourlon, Maria T., et al.
Publicado: (2016)

Erythema multiforme major induced by sunitinib for metastatic renal cell carcinoma
por: Watanabe, Daisuke, et al.
Publicado: (2019)

Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib
por: Cebrián, Arancha, et al.
Publicado: (2017)

Real-world evidence on first-line treatment for metastatic renal cell carcinoma with non-clear cell and sarcomatoid histologies: are sunitinib and pazopanib interchangeable?
por: Bonadioa, Renata Colombo, et al.
Publicado: (2019)

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma
por: Rini, Brian I, et al.
Publicado: (2022)

Efficacy and Safety of First-Line Cytokines versus Sunitinib and Second-Line Axitinib for Patients with Metastatic Renal Cell Carcinoma (ESCAPE Study): A Phase III, Randomized, Sequential Open-Label Study
por: Kadono, Yoshifumi, et al.
Publicado: (2023)

The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma
por: Song, Yan, et al.
Publicado: (2021)

Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study
por: Lindskog, Magnus, et al.
Publicado: (2022)

Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma
por: Bianconi, Maristella, et al.
Publicado: (2016)

Cost-Effectiveness of the First Line Treatment Options For Metastatic Renal Cell Carcinoma in India
por: Gupta, Dharna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_k16aorpc57poau65m7fv900h6o